NANOMEDICINE RESEARCH CORE (NRC)

纳米医学研究核心 (NRC)

• 批准号: 8357112
• 负责人: Mandip Singh Sachdeva
• 金额: $ 25.75万
• 依托单位: FLORIDA AGRICULTURAL AND MECHANICAL UNIV
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-06-01 至 2012-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357112
• 关键词: Alzheimer' s Disease; Area; Basic Science; Biological Products; Chronic Fatigue Syndrome; Clinical; Collaborations; Communities; Degenerative Disorder; Disease; Drug Delivery Systems; Drug Formulations; Drug Kinetics; Equipment; Evaluation; Florida; Funding; Future; Goals; Grant; Growth; Historically Black Colleges and Universities; Human Resources; Image; Malignant Neoplasms; Minority; Mission; National Center for Research Resources; Outcome; Pharmacologic Substance; Pharmacy (field); Pharmacy facility; Principal Investigator; Research; Research Activity; Research Infrastructure; Research Personnel; Resources; Scientist; Series; Source; Stroke; Technology; Training; Translating; United States National Institutes of Health; Universities; bench to bedside; college; cost; innovation; nanomedicine; nanoparticle; programs; receptor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. ABSTRACT: Nanomedicine Research Activity (NRA) is an extended outcome of the previously funded Drug Delivery Activity by the RCMI program. The last several years have seen significant growth in the drug delivery and pharmaceutics area at the College of Pharmacy, FAMU. The objective and mission of the drug delivery activity has been to give the scientific community at FAMU the requisite support to excel in targeted drug delivery. Currently, we have established basic infrastructure in the area of drug delivery and the future direction of this activity is to develop expertise in the emerging area of Nanomedicine by focusing specifically in the area of nanoparticles. The Long-term goal of this activity is to establish resources and expertise in the area of nanoparticle technology which could be applied to imaging of various degenerative diseases like Alzheimer and stroke and also to target various receptors in disease states like cancer and chronic fatigue syndrome. The specific aims of this activity are: Specific Aim 1: Establish suitable infrastructure for nanoparticle drug delivery research by hiring key personnel and equipment. Specific Aim 2: To develop collaborations between research investigators with basic science and clinical backgrounds to develop innovative drug delivery technologies which can be translated from bench to bedside. Specific Aim 3: To develop resources and expertise for biopharmaceutical and pharmacokinetic evaluation of drugs and formulations. Specific Aim 4: Provide opportunities for the training of minority scientists in the area of nanoparticle formulation and delivery. These capabilities will strengthen the infrastructure and enable the investigators at historically black institutions like Florida A&M University to be able to attract extra-mural funding like R-series grants.

该子项目是利用资源的众多研究子项目之一 由 NIH/NCRR 资助的中心拨款提供。子项目的主要支持 并且子项目的主要研究者可能是由其他来源提供的， 包括其他 NIH 来源。 子项目可能列出的总成本 代表子项目使用的中心基础设施的估计数量， NCRR 赠款不直接向子项目或子项目工作人员提供资金。 抽象的： 纳米医学研究活动 (NRA) 是 RCMI 计划先前资助的药物输送活动的延伸成果。过去几年，FAMU 药学院的药物输送和药剂学领域取得了显着增长。药物输送活动的目标和使命是为 FAMU 的科学界提供必要的支持，以在靶向药物输送方面取得优异的成绩。目前，我们已经在药物输送领域建立了基础设施，这项活动的未来方向是通过特别关注纳米颗粒领域来发展纳米医学新兴领域的专业知识。这项活动的长期目标是在纳米颗粒技术领域建立资源和专业知识，可应用于阿尔茨海默病和中风等各种退行性疾病的成像，并针对癌症和慢性疲劳综合症等疾病状态的各种受体。该活动的具体目标是： 具体目标 1：通过雇用关键人员和设备，为纳米颗粒药物输送研究建立合适的基础设施。具体目标 2：发展具有基础科学和临床背景的研究人员之间的合作，开发可从实验室转化为临床的创新药物输送技术。具体目标 3：为药物和制剂的生物制药和药代动力学评价开发资源和专业知识。具体目标 4：为少数族裔科学家提供纳米颗粒配制和输送领域的培训机会。这些能力将加强基础设施，并使佛罗里达农工大学等历史悠久的黑人机构的调查人员能够吸引 R 系列拨款等校外资金。